Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Surveillance and Epidemiologic Research of Duchenne and Becker Muscular Dystrophy and Other Single Gene Disorders, Request for Applications (RFA) Number DD06-002, 31192 [E6-8443]

Download as PDF 31192 Federal Register / Vol. 71, No. 105 / Thursday, June 1, 2006 / Notices facilities in order to estimate the average variable costs of providing colonoscopy and flexible sigmoidoscopy for CRC screening and follow-up services. Over time, payments need to cover fixed costs in addition to variable costs. If some facilities have the ability to provide more procedures without additional investment in space or equipment, then recovering fixed costs is not necessary at least in the short run. The estimated average variable cost by procedure will be compared to the reimbursement rates for both screening procedures in order to determine whether the payments to facilities exceed this minimum threshold. Otherwise, facilities will find reimbursement a potential barrier to expansion of CRC screening to uninsured or underinsured populations even if there is underutilized capacity. The study will also determine whether there are factors that affect average variable costs across facilities such as the number of procedures performed, specialization in types of procedures or other characteristics of the facility. Results of this study will be used to better understand the economics of colorectal cancer screening. Respondents include medical facility receptionists, hospital operators, and office/business managers. There is no cost to the respondent, other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Form type Number of respondents Number of responses per respondent Average burden per response (in hours) Telephone script to medical facility receptionists ............................................ Mail Survey to hospital-based outpatient department managers .................... Mail Survey to ambulatory surgery center managers ..................................... Total .......................................................................................................... 4,160 1,000 725 ........................ 1 1 1 ........................ 5/60 1 1 ........................ Dated: May 24, 2006. Joan F. Karr, Acting Report Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E6–8453 Filed 5–31–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Surveillance and Epidemiologic Research of Duchenne and Becker Muscular Dystrophy and Other Single Gene Disorders, Request for Applications (RFA) Number DD06–002 wwhite on PROD1PC61 with NOTICES In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting: Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Surveillance and Epidemiologic Research of Duchenne and Becker Muscular Dystrophy and Other Single Gene Disorders, Request for Applications (RFA) Number DD06–002. Time and Date: 12 p.m.–5 p.m., June 27, 2006 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: To conduct expert review of scientific merit of research VerDate Aug<31>2005 20:00 May 31, 2006 Jkt 208001 applications: Surveillance and Epidemiologic Research of Duchenne and Becker Muscular Dystrophy and Other Single Gene Disorders, RFA Number DD06–002. FOR FURTHER INFORMATION CONTACT: Juliana Cyril, PhD., Scientific Review Administrator, Centers for Disease Control, 1600 Clifton Road, NE., Mail Stop D–72, Atlanta, GA 30333, Telephone 404.639.4639. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: May 24, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6–8443 Filed 5–31–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Research and Development Contract Attention Deficit Hyperactivity Disorder Surveillance, Contract Solicitation Number (CSN) 2006–N–08468 In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 Total burden hours 347 1,000 725 2,072 Control and Prevention (CDC) announces the following meeting: Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Research and Development Contract Attention Deficit Hyperactivity Disorder Surveillance, CSN 2006–N–08468. Time and Date: 12 p.m.–4 p.m., June 22, 2006 (Closed). Place: Centers for Disease Control, 1600 Clifton Road NE., Building 19, Room 8123, Atlanta, GA 30333. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to ‘‘Research and Development Contract Attention Deficit Hyperactivity Disorder Surveillance,’’ CSN 2006–N–08468. Contact Person for More Information: Christine Morrison, Ph.D., Scientific Review Administrator, Office of Extramural Research, CDC, 1600 Clifton Road NE., Mailstop D72, Atlanta, GA 30333, Telephone 404–639–3098. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: May 24, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6–8444 Filed 5–31–06; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\01JNN1.SGM 01JNN1

Agencies

[Federal Register Volume 71, Number 105 (Thursday, June 1, 2006)]
[Notices]
[Page 31192]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-8443]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panels (SEP): Surveillance and Epidemiologic Research of 
Duchenne and Becker Muscular Dystrophy and Other Single Gene Disorders, 
Request for Applications (RFA) Number DD06-002

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting:

    Name: Disease, Disability, and Injury Prevention and Control 
Special Emphasis Panel (SEP): Surveillance and Epidemiologic 
Research of Duchenne and Becker Muscular Dystrophy and Other Single 
Gene Disorders, Request for Applications (RFA) Number DD06-002.
    Time and Date: 12 p.m.-5 p.m., June 27, 2006 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters to be Discussed: To conduct expert review of scientific 
merit of research applications: Surveillance and Epidemiologic 
Research of Duchenne and Becker Muscular Dystrophy and Other Single 
Gene Disorders, RFA Number DD06-002.

FOR FURTHER INFORMATION CONTACT: Juliana Cyril, PhD., Scientific Review 
Administrator, Centers for Disease Control, 1600 Clifton Road, NE., 
Mail Stop D-72, Atlanta, GA 30333, Telephone 404.639.4639.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: May 24, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E6-8443 Filed 5-31-06; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.